Hypericin-functionalized graphene oxide for enhanced mitochondria-targeting and synergistic anticancer effect

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• Targeting mitochondria is a key strategy in cancer therapy.
• Mitochondria are challenging to access due to their double membrane and negative potential.
• Developing effective mitochondria-targeting ligands is crucial for improved cancer treatment.

Purpose of the Study:

• To investigate hypericin as a novel mitochondria-targeting ligand.
• To develop a dual-delivery system of hypericin and doxorubicin on graphene oxide for synergistic cancer therapy.
• To evaluate the efficacy and safety of this system in targeting breast carcinoma cells.

Main Methods:

• Functionalization of graphene oxide (GO) with hypericin (HY) and doxorubicin (DOX).
• In vitro and in vivo assays to assess cellular uptake, apoptosis induction, and antitumor efficacy.
• Evaluation of toxicity in normal cells and tumor cells.

Main Results:

• HY-functionalized GO loaded with DOX (GO-PEG-SS-HY/DOX) demonstrated enhanced synergistic anticancer efficacy.
• The treatment induced mitochondria-mediated apoptosis in breast carcinoma cells (MDA-MB-231 and MCF-7).
• The GO vehicle exhibited low toxicity toward normal cells, indicating high safety.

Conclusions:

• Hypericin is an effective mitochondria-targeting ligand for cancer therapy.
• HY-functionalized GO serves as a promising platform for targeted drug delivery.
• This approach improves the therapeutic efficacy of chemotherapeutic drugs with reduced side effects.